NCT00386516 2017-08-01Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerGalectin Therapeutics Inc.Phase 2 Withdrawn
NCT01859182 2014-09-09Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 2 Withdrawn